We explored the potential of a synthetic peptide, derived from lactoferrin, to treat multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. This peptide mimics the antibacterial properties of lactoferrin and appears to have anticancer effects as well.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
Helps canine cancer
Most Useful Review
The product works well for me; I give it to my dog who has cancer, and it seems to be beneficial. The service has also been commendable.